BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 24, 2013
View Archived Issues
Romark Laboratories commences enrollment in phase III trial of nitazoxanide for influenza
Read More
Impel NeuroPharma completes proof-of-concept study for nose-to-brain drug delivery technology
Read More
New prostate cancer vaccine is safe in patients
Read More
Galectin-9, a marker of radicality of cancer resection during surgery
Read More
Bayer presents novel AR antagonist with promising in vivo activity in CRPC models
Read More
Paragazole is active against triple-negative breast cancer cells
Read More
Dosing begins in phase I/II anal cancer study of ADXS-HPV
Read More
Dainippon Sumitomo Pharma presents novel mAChR partial agonists as potential antipsychotic drugs
Read More
ASLAN Pharmaceuticals to conduct antiarthritic drug study in Singapore
Read More
Companies fund Canadian Centers of Excellence for Commercialization and Research
Read More
Galapagos begins first phase II study of GLPG-0974 in ulcerative colitis
Read More
Afferent Pharmaceuticals profiles its P2X3 receptor antagonist AF-219
Read More
Merck KGaA presents novel LPA2 receptor antagonists
Read More
New CYP17 inhibitors patented at Bristol-Myers Squibb
Read More
Oncodesign discovers novel FLT3 inhibitors
Read More
Presentations describe novel mutant-selective EGFR inhibitor CNX-2006
Read More
NanoViricides anticipates efficacy of FluCide drug candidates against H7N9 influenza
Read More
Taiho Pharmaceutical designs new SYK inhibitors
Read More
Ipsen and Oncodesign prepare novel LRRK2 inhibitors
Read More
Janssen files for European approval of simeprevir for HCV
Read More
Enrollment begins in phase I trial of Acorda's remyelinating antibody candidate for MS
Read More
Takeda files for approval of fixed-dose combination drug for hypertension in Japan
Read More
FDA approves Amitiza for additional indication
Read More
CytRx reaches SPA agreement with FDA for phase III trial of aldoxorubicin
Read More
FDA grants fast track designation to KB-001A for P. aeruginosa
Read More